Simvastatin as a novel therapeutic agent for venous ulcers: a randomized, double-blind, placebo-controlled trial

201447 citationsJournal Article

Authors

Mara Therese P. Evangelista · José R. Reyes Memorial Medical Center

M.F.A. Casintahan · José R. Reyes Memorial Medical Center

Lillian L. Villafuerte · José R. Reyes Memorial Medical Center

Abstract

Simvastatin 40 mg daily, in addition to standard wound care and compression, is associated with a significant improvement in healing rate and time, as well as an improved patient quality of life when compared with placebo in the management of venous ulcers.

Topics & Keywords

Diagnosis and Treatment of Venous Diseases Venous Thromboembolism Diagnosis and Management Wound Healing and Treatments

UN Sustainable Development Goals

Responsible consumption and production

Publication Details

Published in: British Journal of Dermatology

Volume 170, Issue 5, pp. 1151-1157

DOI: 10.1111/bjd.12883

Field-Weighted Citation Impact: 5.43